Table 1.
GI50 and TGI of compound 8v against the panel of 58 cell lines representing 9 different cancers tested using NCI’s in vitro five dose anticancer assay.
| Panel/Cell Line | GI50 (μM) | TGI (μM) | Panel/Cell Line | GI50 (μM) | TGI (μM) |
|---|---|---|---|---|---|
| Leukemia | Melanoma | ||||
| CCRF-CEM | 1.84 | 4.56 | LOX IMVI | 0.32 | 1.28 |
| HL-60(TB) | 2.00 | 4.10 | MALME-3M | 1.68 | 3.45 |
| MOLT-4 | 2.05 | 5.27 | M14 | 1.60 | 3.30 |
| RPMI-8226 | 1.73 | 4.31 | MDA-MB-435 | 1.70 | 3.40 |
| SR | 1.86 | 4.01 | SK-MEL-2 | 1.79 | 4.82 |
| Non-Small Cell Lung Cancer | SK-MEL-28 | 1.74 | 3.40 | ||
| A549/ATCC | 1.84 | 3.53 | SK-MEL-5 | 2.14 | 5.24 |
| EKVX | 1.79 | 3.98 | UACC-257 | 2.16 | 4.69 |
| HOP-62 | 2.13 | 4.53 | UACC-62 | 1.73 | 3.43 |
| HOP-92 | 1.93 | 4.23 | Ovarian Cancer | ||
| NCI-H226 | 2.67 | 5.69 | IGROV1 | 1.54 | 3.75 |
| NCI-H23 | 1.88 | 3.97 | OVCAR-3 | 1.78 | 3.38 |
| NCI-H322M | 1.59 | 2.98 | OVCAR-4 | 2.00 | 4.62 |
| NCI-H460 | 2.00 | 3.85 | OVCAR-5 | 1.72 | 3.30 |
| NCI-H522 | 1.55 | 3.21 | OVCAR-8 | 2.32 | 5.73 |
| Colon Cancer | NCI/ADR-RES | 2.42 | 7.03 | ||
| COLO 205 | 1.94 | 3.84 | SK-OV-3 | 2.42 | 5.68 |
| HCC-2998 | 1.88 | 3.65 | Renal Cancer | ||
| HCT-116 | 0.50 | 1.94 | 786–0 | 1.70 | 3.36 |
| HCT-15 | 1.63 | 3.22 | A498 | 11.00 | 23.60 |
| HT29 | 1.83 | 3.62 | ACHN | 1.72 | 3.22 |
| KM12 | 1.77 | 3.40 | RXF 393 | 1.74 | 3.54 |
| SW-620 | 1.86 | 3.60 | SN12C | 1.83 | 3.57 |
| CNS cancer | TK-10 | 1.52 | 3.03 | ||
| SF-268 | 1.79 | 3.96 | UO-31 | 1.46 | 2.97 |
| SF-295 | 1.77 | 3.35 | Breast cancer | ||
| SF-539 | 1.64 | 3.03 | MCF7 | 1.27 | 3.68 |
| SNB-19 | 1.78 | 3.56 | MDA-MB231/ATCC | 1.82 | 3.50 |
| SNB-75 | 1.47 | 3.15 | HS 578T | 2.65 | 7.76 |
| U251 | 1.68 | 3.18 | BT-549 | 1.40 | 2.81 |
| Prostate Cancer | T-47D | 2.05 | 5.08 | ||
| PC-3 | 1.75 | 3.30 | MDA-MB-468 | 2.10 | 5.02 |
| DU-145 | 1.75 | 3.21 | |||